Cargando…

Strain Identification and Drug Resistance Analysis of Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry in Nontuberculous Mycobacterial Lung Disease

OBJECTIVE: To evaluate the clinical value of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) in detecting Nontuberculous mycobacteria (NTM). METHODS: The clinical data of 172 patients with suspected NTM lung disease were collected from our hospital from Ja...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Jichan, Gao, Gexin, Pan, Jing, Wu, Lian-Peng, Ning, Hongye, Wu, Zhengxin, Ye, Xinchun, Jiang, Xiangao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361085/
https://www.ncbi.nlm.nih.gov/pubmed/37484902
http://dx.doi.org/10.2147/IDR.S405563
_version_ 1785076155220492288
author Shi, Jichan
Gao, Gexin
Pan, Jing
Wu, Lian-Peng
Ning, Hongye
Wu, Zhengxin
Ye, Xinchun
Jiang, Xiangao
author_facet Shi, Jichan
Gao, Gexin
Pan, Jing
Wu, Lian-Peng
Ning, Hongye
Wu, Zhengxin
Ye, Xinchun
Jiang, Xiangao
author_sort Shi, Jichan
collection PubMed
description OBJECTIVE: To evaluate the clinical value of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) in detecting Nontuberculous mycobacteria (NTM). METHODS: The clinical data of 172 patients with suspected NTM lung disease were collected from our hospital from January 1, 2018, to December 30, 2021. The results were compared with those of BACTEC MGIT 960 in liquid culture and gene chip. This study also utilised MALDI-TOF MS to detect macrolide (MA) and amikacin (Am) mutations. RESULTS: One hundred thirty-seven cases of NTM pulmonary disease were confirmed by identifying the NTM gene chip in bronchoalveolar lavage fluid and/or MALDI-TOF MS detection. The positive predictive value and negative predictive value were 100% (131/131) and 85.37% (35/41), respectively, and the consistency of the two methods was high (kappa=0.899). For the drug resistance detection of MAs, the consistency rate between MALDI-TOF MS detection and drug sensitivity detection was 97.71% (128/131), the sensitivity was 81.25% (13/16) and the specificity was 100% (115/115). The positive and negative predictive values were 100% (13/13) and 93.75% (115/118), respectively. There was no coincidental consistency between the two methods, and the consistency was high (P<0.001, kappa=0.884). For the drug resistance test of Am, the consistency rate between the MALDI-TOF MS test and the drug sensitivity test was 93.13% (122/131), the sensitivity was 93.52% (101/108), the specificity was 90.91% (21/23) and the positive predictive value and negative predictive value were 98.06% (101/103) and 75.00% (21/28), respectively. The two methods had high consistency, and the consistency was not coincidental (P<0.001, kappa=0.781). CONCLUSION: Utilising MALDI-TOF MS has a good consistency with the drug resistance gene chip method and can be a rapid and effective method to identify strains and drug resistance of NTM. Therefore, it has certain clinical application value in patients with suspected NTM lung disease.
format Online
Article
Text
id pubmed-10361085
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-103610852023-07-22 Strain Identification and Drug Resistance Analysis of Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry in Nontuberculous Mycobacterial Lung Disease Shi, Jichan Gao, Gexin Pan, Jing Wu, Lian-Peng Ning, Hongye Wu, Zhengxin Ye, Xinchun Jiang, Xiangao Infect Drug Resist Original Research OBJECTIVE: To evaluate the clinical value of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) in detecting Nontuberculous mycobacteria (NTM). METHODS: The clinical data of 172 patients with suspected NTM lung disease were collected from our hospital from January 1, 2018, to December 30, 2021. The results were compared with those of BACTEC MGIT 960 in liquid culture and gene chip. This study also utilised MALDI-TOF MS to detect macrolide (MA) and amikacin (Am) mutations. RESULTS: One hundred thirty-seven cases of NTM pulmonary disease were confirmed by identifying the NTM gene chip in bronchoalveolar lavage fluid and/or MALDI-TOF MS detection. The positive predictive value and negative predictive value were 100% (131/131) and 85.37% (35/41), respectively, and the consistency of the two methods was high (kappa=0.899). For the drug resistance detection of MAs, the consistency rate between MALDI-TOF MS detection and drug sensitivity detection was 97.71% (128/131), the sensitivity was 81.25% (13/16) and the specificity was 100% (115/115). The positive and negative predictive values were 100% (13/13) and 93.75% (115/118), respectively. There was no coincidental consistency between the two methods, and the consistency was high (P<0.001, kappa=0.884). For the drug resistance test of Am, the consistency rate between the MALDI-TOF MS test and the drug sensitivity test was 93.13% (122/131), the sensitivity was 93.52% (101/108), the specificity was 90.91% (21/23) and the positive predictive value and negative predictive value were 98.06% (101/103) and 75.00% (21/28), respectively. The two methods had high consistency, and the consistency was not coincidental (P<0.001, kappa=0.781). CONCLUSION: Utilising MALDI-TOF MS has a good consistency with the drug resistance gene chip method and can be a rapid and effective method to identify strains and drug resistance of NTM. Therefore, it has certain clinical application value in patients with suspected NTM lung disease. Dove 2023-07-17 /pmc/articles/PMC10361085/ /pubmed/37484902 http://dx.doi.org/10.2147/IDR.S405563 Text en © 2023 Shi et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Shi, Jichan
Gao, Gexin
Pan, Jing
Wu, Lian-Peng
Ning, Hongye
Wu, Zhengxin
Ye, Xinchun
Jiang, Xiangao
Strain Identification and Drug Resistance Analysis of Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry in Nontuberculous Mycobacterial Lung Disease
title Strain Identification and Drug Resistance Analysis of Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry in Nontuberculous Mycobacterial Lung Disease
title_full Strain Identification and Drug Resistance Analysis of Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry in Nontuberculous Mycobacterial Lung Disease
title_fullStr Strain Identification and Drug Resistance Analysis of Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry in Nontuberculous Mycobacterial Lung Disease
title_full_unstemmed Strain Identification and Drug Resistance Analysis of Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry in Nontuberculous Mycobacterial Lung Disease
title_short Strain Identification and Drug Resistance Analysis of Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry in Nontuberculous Mycobacterial Lung Disease
title_sort strain identification and drug resistance analysis of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in nontuberculous mycobacterial lung disease
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361085/
https://www.ncbi.nlm.nih.gov/pubmed/37484902
http://dx.doi.org/10.2147/IDR.S405563
work_keys_str_mv AT shijichan strainidentificationanddrugresistanceanalysisofmatrixassistedlaserdesorptionionizationtimeofflightmassspectrometryinnontuberculousmycobacteriallungdisease
AT gaogexin strainidentificationanddrugresistanceanalysisofmatrixassistedlaserdesorptionionizationtimeofflightmassspectrometryinnontuberculousmycobacteriallungdisease
AT panjing strainidentificationanddrugresistanceanalysisofmatrixassistedlaserdesorptionionizationtimeofflightmassspectrometryinnontuberculousmycobacteriallungdisease
AT wulianpeng strainidentificationanddrugresistanceanalysisofmatrixassistedlaserdesorptionionizationtimeofflightmassspectrometryinnontuberculousmycobacteriallungdisease
AT ninghongye strainidentificationanddrugresistanceanalysisofmatrixassistedlaserdesorptionionizationtimeofflightmassspectrometryinnontuberculousmycobacteriallungdisease
AT wuzhengxin strainidentificationanddrugresistanceanalysisofmatrixassistedlaserdesorptionionizationtimeofflightmassspectrometryinnontuberculousmycobacteriallungdisease
AT yexinchun strainidentificationanddrugresistanceanalysisofmatrixassistedlaserdesorptionionizationtimeofflightmassspectrometryinnontuberculousmycobacteriallungdisease
AT jiangxiangao strainidentificationanddrugresistanceanalysisofmatrixassistedlaserdesorptionionizationtimeofflightmassspectrometryinnontuberculousmycobacteriallungdisease